Recent Posts
- Another Two-Plasmid AAV Gene Therapy Enters Clinical Trial: Gene Vector Biotechnology’s JWK001 Pioneers in Treating nAMD
- Accelerating Gene Therapy Production: Combining next-generation AAV vectors and artificial intelligence (AI)
- REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
- FDA is investigating whether CAR-T, a cancer therapy pioneered at Penn, can cause lymphoma
- Clinicians say benefits of CAR-T continue to outweigh risk of T-cell malignancies
AAV One-stop Solution
Tags
AAV1.NT-3
AAV2
AAV5
AAV based gene therapy
AAV Capsid
ALS
Alzheimer’s Disease
brain vasculature
CAR-T
Cell Therapy
chylomicronemia syndrome
COVID-19
COVID vaccine
CRISPR
CRISPR/Cas
dystrophin
eye disease
FDA
gene editing
gene therapy
genetic engineering
genome editing
GMP AAV
GMP plasmid
heart disease
hemophilia
hepatitis research
HIV
liver cancer
mRNA
muscular dystrophy
Neurodegenerative Diseases
Parkinson
PD-1
protein BVES
rare disease
Retinoschisis
RNA
RNAi therapeutics
RNA vaccines
sarcopenia
SARS-CoV-2
SMA Treatment
thyroid
zolgensma